Sun 2000.

Methods	Allocation: randomised. Blindness: not described. Duration: 6 weeks. Setting:no details.
Participants	Diagnosis: schizophrenia CCMD‐2‐R. N = 103. Age: mean 31 ± 9 years. Sex: male and female, History: length of illness not stated. Included: not stated. Excluded: not stated. Consent: not stated.
Interventions	1. Perphenazine: 8‐60 mg/day, n = 51. 2. Clozapine: 50‐600 mg/day, n = 51. 3. Perphenazine + clozapine: 32‐50 mg/day + 100‐300 mg/day, n = 51.
Outcomes	Curative effect (improvement: cured = psychiatric symptoms disappeared, insight recovered, BPRS reduction >80%; markedly improved = majority of symptoms disappear, some insight, BPRS reduction > 60% to 79%; improvement = some psychiatric symptoms disappeared, no insight, BPRS reduction > 30% to 59%; no effect = no change/ worse symptoms, BPRS reduction < 30%. BPRS, TESS score, adverse events.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised – no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details.
Selective reporting (reporting bias)	Unclear risk	No details.
Other bias	Unclear risk	No details as to blinding; two raters involved in administering BPRS and TESS.